Clinical trial · Interventional
Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study
TREATS: Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being done to find out if video consultations (telemedicine) can be used to safely and effectively assess and manage skin problems caused by cancer treatments. Instead of always coming to the hospital for a face-to-face appointment, the patient may be able to use thier smartphone or computer to show your skin to a nurse or doctor over a secure video call. the researchers want to see if this is as good as a regular clinic visit, and whether patients and staff are happy with this new way of working.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rash | — | UNRESOLVED | — |
| Systemic Treatments | — | UNRESOLVED | — |
| Tele-assessment | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| telem healthassessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Remote tele medicine assessment
- description
- use of telemedicine
- interventionNames
- Other: telem healthassessment
Primary outcomes (1)
- measure
- time to clinical resolution
- timeFrame
- 6 weeks
- description
- Number of days from first AHOS contact to documented resolution (Grade 0-1).
Secondary outcomes (4)
- measure
- Escalation in person review
- timeFrame
- 6 weeks
- description
- Proportion of telemedicine patients requiring: * Conversion to face-to-face review * Emergency department attendance * Hospital admission
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria:Participants must meet all of the following criteria: * Adult oncology or haematology patients currently receiving systemic anti-cancer therapy (SACT). * New-onset dermatologic toxicity consistent with a recognised adverse effect of the administered SACT. * Skin toxicity severity graded ≤ Grade 2 in accordance with UKONS assessment criteria. * Clinically stable condition not requiring urgent in-person evaluation. * Access to, and ability to use, a smartphone or computer with adequate internet connectivity to participate in telemedicine consultations. Exclusion Criteria: Participants will be excluded if any of the following criteria apply: * Skin toxicity graded ≥ Grade 3 according to UKONS assessment criteria. * Clinical status requiring urgent or immediate face-to-face medical assessment. * Dermatologic toxicity that is atypical, unexpected, or not consistent with known SACT-related adverse effects. * Inability to access or effectively use the required telemedicine technology.
References
Publications (0)
Data not yet available